SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ |
|
FORM 8-K |
CURRENT REPORT
|
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
________________ |
|
Date of Report (Date of earliest event reported): May 6, 2004
|
Alpharma Inc.
|
|
(Exact name of registrant as specified in its charter) |
|
Delaware (State or other jurisdiction of incorporation) | 1-8593 (Commission File Number) | 22-2095212 (IRS Employer Identification) |
|
One Executive Drive, Fort Lee, New Jersey 07024 (Address of principal executive offices) (Zip Code) |
|
Registrant's telephone number, including area code (201) 947-7774 |
|
|
Not Applicable |
______________________________________________ (Former name or former address, if changed since |
last report) |
Item 5. Other Events.
On May 6, 2004, the Company issued a press release announcing that it intends to restate its consolidated financial statements for the quarters ended March 31, June 30 and September 30, 2003 and for the year ended December 31, 2003. A copy of this press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statement and Exhibits
(c) Exhibits.
Press release issued by Alpharma Inc. on May 6, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALPHARMA INC.
/s/ Matthew T. Farrell |
| By: /s/ Matthew T. Farrell |
| Matthew T. Farrell Executive Vice President and Chief Financial Officer |
Date: May 6, 2004